SCHEMBL26488683

SCHEMBL26488683

CCOC(=O)/C=C/c1cc2cc(NS(=O)(=O)c3ccc(C(C)(C)C)cc3)ccc2s1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
HIF1A Q16665 1/20 0.49
HDAC1 Q13547 1/20 0.48
ALDH1A1 P00352 3/20 0.46
LMNA P02545 1/20 0.46
PTPN5 P54829 1/20 0.44
POLB P06746 1/20 0.44
UQCRB P14927 2/20 0.42
IKBKB O14920 1/20 0.42
PPARG P37231 1/20 0.42
PPARA Q07869 1/20 0.42
HDAC3 O15379 2/20 0.42
HDAC11 Q96DB2 2/20 0.42
HDAC8 Q9BY41 2/20 0.42
HDAC6 Q9UBN7 2/20 0.42
GHSR Q92847 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30372693 1.00 MAPT (0.50) MAPTMEN1KMT2AHIF1AHDAC1
SCHEMBL26488673 0.91 MAPT (0.59) MAPTMEN1KMT2AHIF1AHDAC1
SCHEMBL26488662 0.89 KMT2A (0.48) MAPTMEN1KMT2AHDAC1ALDH1A1
SCHEMBL30373016 0.89 KMT2A (0.48) MAPTMEN1KMT2AHDAC1ALDH1A1
SCHEMBL23883383 0.86 HDAC1 (0.53) MAPTMEN1KMT2AHDAC1ALDH1A1
SCHEMBL22718808 0.86 HDAC1 (0.53) MAPTMEN1KMT2AHDAC1ALDH1A1
SCHEMBL22718732 0.85 HDAC1 (0.52) MAPTMEN1KMT2AHDAC1ALDH1A1
SCHEMBL30372215 0.84 MAPT (0.48) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL26488691 0.84 MAPT (0.48) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL23898763 0.83 ESR1 (0.37) MAPTALDH1A1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230131501-A1 THERAPEUTIC USES OF INHIBITORS OF THE RNA-BINDING PROTEIN HuR UNIVERSITY OF KANSAS 2023-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230131501-A1 THERAPEUTIC USES OF INHIBITORS OF THE RNA-BINDING PROTEIN HuR HNRNPH1, ELAVL1, RBM3 MAPT 2784/4885MEN1 2590/4885KMT2A 2237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.